~~<i id='7CAE685F3F'><strike id='7CAE685F3F'><tt id='7CAE685F3F'><pre id='7CAE685F3F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：hotspot 2025-08-06 04:47:19 - browse：26996

A new Ebola epidemic in the Democratic Republic of the Congo is shaping up to be the most dangerous and difficult test of the world’s ability to contain the disease since the catastrophic West African outbreak in 2014 and 2015. What challenges are responders facing? And how might experimental vaccines be used to try to slow the spread of the epidemic?

See below for an archived chat with Helen Branswell about these issues and more.

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Should insurance cover cosmetic surgery?

focus

leisure time

focus

hotspot

focus

explore

JoeRaedle/GettyImagesAfewyearsagoatalargeteachinghospitalinTexas,amedicalresidentaskedanursehowtoord

WSS

Food makers to regulators: Ultra

New Covid vaccine is recommended for everyone 6 months or older

WATCH: Why do bright lights make us see spots?

Some medical students still think black patients feel less pain

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Clinicians often fail to acknowledge the pain caused by long Covid

focus

entertainment

focus

Psychedelics group wrestles with new pharma identity

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Medical records are filled with copy

The world needs the new pandemic treaty

Hollywood unions extend contract negotiations for actors

Generate Biomedicines machine learning biotech raises $273M

BioMarin wins approval for gene therapy to treat hemophilia A

Hospitals consider fixing cancer drug shortages on their own

Novavax promises a turnaround & Lilly roils the obesity market

Why we need mandatory labeling of GMO products

leisure time

FDA approves updated Covid vaccines

What to make of Biden’s latest efforts on cancer research

What to make of Biden’s latest efforts on cancer research

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Telehealth for opioid use disorder is lifesaving

White House touts steps to stem shortages of cancer treatments

focus

hotspot

focus

explore